<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34932653</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1678-4227</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Arquivos de neuro-psiquiatria</Title><ISOAbbreviation>Arq Neuropsiquiatr</ISOAbbreviation></Journal><ArticleTitle>Quality of life, disability, and clinical variables in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>255</StartPage><EndPage>261</EndPage><MedlinePgn>255-261</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/0004-282X-ANP-2021-0201</ELocationID><Abstract><AbstractText Label="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a motor neuron disease that results in a progressive increase in dysfunctions, limitations and restrictions over time, which can impact on quality of life (QoL). Therefore, expanding knowledge on QoL and possible factors associated with ALS can enable the development of actions to ensure greater wellbeing for the population.</AbstractText><AbstractText Label="OBJECTIVE">To investigate QoL in ALS and determine associations with demographic, functional and clinical aspects.</AbstractText><AbstractText Label="METHODS">Forty-five individuals with ALS (56.4&#xb1;11.1 years) participated in the study. Demographic, clinical and functional aspects were investigated. Functioning and QoL were assessed using disease-specific tools (ALS Functional Ranting Scale-Revised/ALSFRS-R and ALS Assessment Questionnaire/ALSAQ-40). Fatigue was assessed using the Fatigue Severity Scale. Descriptive, correlation and stepwise multiple linear regression analyses were performed with the aid of the SPSS.</AbstractText><AbstractText Label="RESULTS">The mean ALSAQ-40 score was 279.0&#xb1;118.3. QoL was significantly worse among women (p=0.001) and poor QoL was associated with the inability to walk (p=0.014), pain (p=0.021) and disease severity (p&#x2264;0.002). QoL was strongly correlated with the ALSFRS-R score (r=-0.82). Moderate to weak correlations were found for mobility [turning in bed (r=-0.62), locomotion (r=-0.33) and sit to stand (r=-0.40)], strength (r=-0.49), fatigue (r=0.35) and pain (r=-0.32) (p&lt;0.03). The regression analysis revealed that the ALSFRS-R score (&#x3b2;=-0.76; p=0.00) and fatigue (&#x3b2;=0.20; p=0.04) were predictors of QoL.</AbstractText><AbstractText Label="CONCLUSIONS">QoL was worse in women, older people, severe stages of ALS, patients with impaired mobility, those with a poorer physical performance and those who reported pain. Functional status and fatigue are predictors of QoL in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alencar</LastName><ForeName>Mariana Asmar</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-3881-5283</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Fisioterapia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Izaura Monique Moura da</ForeName><Initials>IMMD</Initials><Identifier Source="ORCID">0000-0001-6100-9162</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Fisioterapia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hil&#xe1;rio</LastName><ForeName>St&#xe9;fanie Marcelle</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-8851-5353</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Fisioterapia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rangel</LastName><ForeName>Marcela Ferreira de Andrade</ForeName><Initials>MFA</Initials><Identifier Source="ORCID">0000-0002-0897-2133</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Fisioterapia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdo</LastName><ForeName>Juliana Silva</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-5023-2294</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Fisioterapia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ara&#xfa;jo</LastName><ForeName>Caroline Martins de</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-8866-0374</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Neuroci&#xea;ncia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>Leonardo Cruz de</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0001-5027-9722</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Neuroci&#xea;ncia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Medicina Interna, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Arq Neuropsiquiatr</MedlineTA><NlmUniqueID>0125444</NlmUniqueID><ISSNLinking>0004-282X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="ANTECEDENTES:">Esclerose lateral amiotr&#xf3;fica (ELA) &#xe9; uma doen&#xe7;a do neur&#xf4;nio motor que resulta em um aumento progressivo das disfun&#xe7;&#xf5;es, limita&#xe7;&#xf5;es e restri&#xe7;&#xf5;es ao longo do tempo, o que pode afetar a qualidade de vida (QV). Ampliar o conhecimento sobre QV e os poss&#xed;veis fatores associados permitir&#xe1; o desenvolvimento de a&#xe7;&#xf5;es que garantam maior bem-estar.</AbstractText><AbstractText Label="OBJETIVO:">Avaliar a QV na ELA e verificar a associa&#xe7;&#xe3;o com aspectos demogr&#xe1;ficos, funcionais e cl&#xed;nicos.</AbstractText><AbstractText Label="M&#xc9;TODOS:">Participaram 45 indiv&#xed;duos com ELA (5,4 &#xb1; 11,1 anos). Foram avaliados aspectos demogr&#xe1;ficos, cl&#xed;nicos, funcionais (ALS Functional Ranting Scale-Revised / ALSFRS-R), QV (ALS Assessment Questionnaire/ ALSAQ-40, respectivamente) e fadiga (Escala de gravidade da fadiga). Uma an&#xe1;lise descritiva, correla&#xe7;&#xe3;o e regress&#xe3;o linear m&#xfa;ltipla foram realizadas no programa estat&#xed;stico SPSS.</AbstractText><AbstractText Label="RESULTADOS:">Escore do ALSAQ-40 foi de 279,0 &#xb1; 118,3 para a popula&#xe7;&#xe3;o de ELA avaliada. Verificou-se pior QV significativa em mulheres (p=0,001), incapacidade de andar (p=0,014), dor (p=1,021) e com gravidade da doen&#xe7;a (p&#x2264;0,002). QV correlacionou-se fortemente com ALSFRS-R (r =-0,82) e de moderada a fraca com mobilidade [virar na cama (r =-0,62), locomo&#xe7;&#xe3;o (r =-0,33) e sentar-se em p&#xe9; (r=-0,40)], for&#xe7;a (r=-0,49), fadiga (r=0,35) e dor (r=-0,32) (p&lt;0,03). A an&#xe1;lise de regress&#xe3;o encontrou ALSFRS-R (&#x3b2;=-0,76; p=0,00) e Fadiga (&#x3b2;=0,20; p=0,04) como preditores de QV.</AbstractText><AbstractText Label="CONCLUS&#xd5;ES:">QV estava pior nas mulheres, em idosos, est&#xe1;gios de maior gravidade da ELA, na disfun&#xe7;&#xe3;o de mobilidade, no baixo desempenho e na dor. A funcionalidade e a fadiga na ELA s&#xe3;o preditores de QV.</AbstractText></OtherAbstract><CoiStatement><b>Conflicts of interest:</b> There is no conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>17</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34932653</ArticleId><ArticleId IdType="pmc">PMC9648935</ArticleId><ArticleId IdType="doi">10.1590/0004-282X-ANP-2021-0201</ArticleId><ArticleId IdType="pii">S0004-282X2021005028205</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93(11):P1617&#x2013;P1628. doi: 10.1016/j.mayocp.2018.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J, Kim JA. Supportive care needs of patients with amyotrophic lateral sclerosis/motor neuron disease and their caregivers: a scoping review. J Clinical Nursing. 2017;26(23-24):4129&#x2013;4152. doi: 10.1111/jocn.13945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocn.13945</ArticleId><ArticleId IdType="pubmed">28681543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):639&#x2013;649. doi: 10.1038/nrneurol.2011.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamshiri H, Fatehi F, Abolfazli R, Hariechian MH, Sedighi B, Zamani B, et al. Trends of quality of life changes in amyotrophic lateral sclerosis patients. J Neurol Sci. 2016;368:35&#x2013;40. doi: 10.1016/j.jns.2016.06.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.06.056</ArticleId><ArticleId IdType="pubmed">27538598</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson C, Fitzpatrick R, Brenan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neuron disease: the ALSAQ-40. J Neurol. 1999;246(3):III16&#x2013;III21. doi: 10.1007/BF03161085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03161085</ArticleId><ArticleId IdType="pubmed">10631656</ArticleId></ArticleIdList></Reference><Reference><Citation>Majmudar S, Wu J, Paganoni S. Rehabilitation in amyotrophic lateral sclerosis: why it matters. Muscle Nerve. 2014;50(1):4&#x2013;13. doi: 10.1002/mus.24202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24202</ArticleId><ArticleId IdType="pmc">PMC4433000</ArticleId><ArticleId IdType="pubmed">24510737</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson BJ, Ozanne AG, Nordin K, Nygren I. A prospective study of quality of life in amyotrophic lateral sclerosis patients. Acta Neurol Scand. 2017;136(6):631&#x2013;638. doi: 10.1111/ane.12774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12774</ArticleId><ArticleId IdType="pubmed">28523721</ArticleId></ArticleIdList></Reference><Reference><Citation>Neudert C, Wasner M, Borasio GD. Individual quality of life is not correlated with health-related quality of life or physical function in patients with amyotrophic lateral sclerosis. J Palliat Med. 2004;7(4):551&#x2013;557. doi: 10.1089/jpm.2004.7.551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jpm.2004.7.551</ArticleId><ArticleId IdType="pubmed">15353099</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T, Gaur N, Stubendorff B, R&#xf6;diger A, Witte OW, Grosskreutz J. Disease progression impacts health-related quality of life in amyotrophic lateral sclerosis. J Neurol Sci. 2019;397:92&#x2013;95. doi: 10.1016/j.jns.2018.12.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2018.12.035</ArticleId><ArticleId IdType="pubmed">30597420</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond L, Bowen G, Mertens B, Denson K, Jordan K, Vidakovic B, et al. Associations of patient mood, modulators of quality of life, and pharmaceuticals with amyotrophic lateral sclerosis survival duration. Behav Sci (Basel) 2020;10(1):33. doi: 10.3390/bs10010033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bs10010033</ArticleId><ArticleId IdType="pmc">PMC7016647</ArticleId><ArticleId IdType="pubmed">31936812</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Lizio A, Sansone VA, Cellotto NM, Maestri E, Bettinelli M, et al. Strictly monitored exercise programs reduce motor deterioration in ALS: preliminary results of a randomized controlled trial. J Neurol. 2016;263(1):52&#x2013;60. doi: 10.1007/s00415-015-7924-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7924-z</ArticleId><ArticleId IdType="pubmed">26477027</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavan K, Marangoni BEM, Zinezzi MO, Schmidt ZB, Oliveira BC, Buainais RP, et al. Validation of the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) scale in the portuguese language. Arq Neuropsiquiatr. 2010;68(1):48&#x2013;51. doi: 10.1590/S0004-282X2010000100011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0004-282X2010000100011</ArticleId><ArticleId IdType="pubmed">20339652</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes K, Pereira C, Pavan C, Pavan K, Valerio BCO. Adapta&#xe7;&#xe3;o transcultural e valida&#xe7;&#xe3;o da ALS Functional Rating Scale-revised para l&#xed;ngua portuguesa. Arq Neuropsiquiatr. 2010;68(1):44&#x2013;47. doi: 10.1590/S0004-282X2010000100010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0004-282X2010000100010</ArticleId><ArticleId IdType="pubmed">20339651</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandstedt P, Littorin S, Johansson S, Gottberg K, Ytterberg C, Kierkegaard M. Disability and contextual factors in patients with amyotrophic lateral sclerosis -a three-year observational study. J Neuromuscul Dis. 2018;5(4):439&#x2013;449. doi: 10.3233/JND-180322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-180322</ArticleId><ArticleId IdType="pmc">PMC6218138</ArticleId><ArticleId IdType="pubmed">30282373</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng D, Ou R, Miao X, Zhao L, Wei Q, Chen X, et al. Patients' self-perceived burden, caregivers&#x2019; burden and quality of life for amyotrophic lateral sclerosis patients: a cross-sectional study. J Clin Nurs. 2017;26(19-20):3188&#x2013;3199. doi: 10.1111/jocn.13667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocn.13667</ArticleId><ArticleId IdType="pubmed">27874996</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch F, Skudlarek A, Berndt J, Kornhuber ME. Characteristics of pain in a amyotrophic lateral sclerosis. Brain Behav. 2015;5(3):e00296. doi: 10.1002/brb3.296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.296</ArticleId><ArticleId IdType="pmc">PMC4309879</ArticleId><ArticleId IdType="pubmed">25642388</ArticleId></ArticleIdList></Reference><Reference><Citation>Paternostro-Sluga T, Grim-Stieger M, Posch M, Schuhfried O, Vacariu G, Mittermaier C, et al. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med. 2008;40(8):665&#x2013;671. doi: 10.2340/16501977-0235.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/16501977-0235</ArticleId><ArticleId IdType="pubmed">19020701</ArticleId></ArticleIdList></Reference><Reference><Citation>Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55(4):M221&#x2013;M231. doi: 10.1093/gerona/55.4.M221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/55.4.M221</ArticleId><ArticleId IdType="pubmed">10811152</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo FO, Junior WN, Speciali JG, Sobreira CFDR. Cross-cultural adaptation and validation of the Brazilian version of the fatigue Severity Scale (FSS) Value Health. 2011;14(7):PA329&#x2013;PA330. doi: 10.1016/j.jval.2011.08.532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2011.08.532</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva JPR, Santiago JB, J&#xfa;nior, Dos Santos EL, Carvalho FO, Costa IMPF, et al. Quality of life and functional independence in amyotrophic lateral sclerosis: a systematic review. Neurosci Biobehav Rev. 2020;111:1&#x2013;11. doi: 10.1016/j.neubiorev.2019.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2019.12.032</ArticleId><ArticleId IdType="pubmed">31917162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Haas V. Framework for rehabilitation of neurodegenerative diseases: planning care and maximizing quality of life. Neurology Report. 2002;26(3):115&#x2013;129.</Citation></Reference><Reference><Citation>K&#xf6;rner S, Kollewe K, Abdulla S, Zapf A, Dengler R, Petri S. Interaction of physical function, quality of life and depression in amyotrophic lateral sclerosis: characterization of a large patient cohort. BMC Neurol. 2015;15:84. doi: 10.1186/s12883-015-0340-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-015-0340-2</ArticleId><ArticleId IdType="pmc">PMC4493831</ArticleId><ArticleId IdType="pubmed">25982050</ArticleId></ArticleIdList></Reference><Reference><Citation>Boentert M. Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives. Nat Sci Sleep. 2019;11:97&#x2013;111. doi: 10.2147/NSS.S183504.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NSS.S183504</ArticleId><ArticleId IdType="pmc">PMC6701267</ArticleId><ArticleId IdType="pubmed">31496852</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons C, Pagnini F, Friede T, Young CA. Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2018;1(1):CD0111005. doi: 10.1002/14651858.CD011005.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD011005.pub2</ArticleId><ArticleId IdType="pmc">PMC6494184</ArticleId><ArticleId IdType="pubmed">29293261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou J-S, Reeves A, Benice T, Sexton G. Fatigue and depression are associated with poor quality of life in ALS. Neurology. 2003;60(1):122&#x2013;123. doi: 10.1212/01.wnl.0000042781.22278.0a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000042781.22278.0a</ArticleId><ArticleId IdType="pubmed">12525733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez C, Piemonte MEP, Callegaro D, Silva HCA. Fatigue in amyotrophic lateral sclerosis: frequency and associated factors. Amyotroph Lateral Scler. 2008;9(2):75&#x2013;80. doi: 10.1080/17482960701642502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701642502</ArticleId><ArticleId IdType="pubmed">17924237</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med. 2010;7(6):557&#x2013;570. doi: 10.1016/j.genm.2010.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura MC, Novaes MRCG, Eduardo EJ, Zago YSSP, Freitas RDNB, Casulari LA. Prognostic factors in amyotrophic lateral sclerosis: a population-based study. PLoS One. 2015;10(10):e0141500. doi: 10.1371/journal.pone.0141500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0141500</ArticleId><ArticleId IdType="pmc">PMC4627754</ArticleId><ArticleId IdType="pubmed">26517122</ArticleId></ArticleIdList></Reference><Reference><Citation>Caller TA, Andrews A, Field NC, Henegan PL, Stommel EW. The epidemiology of Amyotrophic lateral sclerosis in New Hampshire, USA, 2004-2007. Neurodegener Dis. 2015;15(4):202&#x2013;206. doi: 10.1159/000374117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000374117</ArticleId><ArticleId IdType="pubmed">25896575</ArticleId></ArticleIdList></Reference><Reference><Citation>Young CA, Ealing J, McDermott C, Williams T, Al-Chalabi A, Majeed T, et al. The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5-6):317&#x2013;327. doi: 10.1080/21678421.2019.1615951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1615951</ArticleId><ArticleId IdType="pubmed">31116037</ArticleId></ArticleIdList></Reference><Reference><Citation>Edge R, Mills R, Tennant A, Diggle PJ, Young CA, TONiC study group Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature. J Neurol. 2020;267(3):607&#x2013;615. doi: 10.1007/s00415-019-09615-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09615-3</ArticleId><ArticleId IdType="pmc">PMC7035222</ArticleId><ArticleId IdType="pubmed">31696295</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>